The incidence of breast cancer has risen over the past 50 years, and it is now the second leading cause of
death among American women. In an attempt to find the reasons for this increase in incidence, genetic,
environmental and dietary factors are being studied. The NF-KB family of dimeric transcription factors, which
controls genes critical for neoplastic transformation, cell proliferation and survival, consists of five members:
3 with transactivation domains (c-Rel, RelA, RelB), and 2 without (p50 and p52), which promote stronger
binding. NF-KB factors are sequestered in the cytoplasm in inactive complexes in most cells. Collaborative
studies by members of the Program Project demonstrated constitutive aberrant activation of c-Rel, RelA or
p50 NF-KB subunits in -90% of primary human breast cancers, and that exposure to polycyclic aromatic
hydrocarbons (PAHs), such as 7,12-dimethylbenz(a)anthracene (DMBA) or benzo(a)pyrene, up-regulated
NF-KB in breast cancer. This led us to the central hypothesis in the original application that carcinogens can
constitutively activate NF-KB, which will promote transformation. In collaboration with Projects 1 and 2, we
have more recently shown that NF-KB complexes, which are induced by PAH exposure, play key roles in
promoting an invasive phenotype of breast cancer via epithelial to mesenchymal transition (EMT). (1) PAH
exposure of mice activated multiple NF-KB complexes, the IKKe/i kinase and an invasive phenotype of mammary
tumors; (2) PAH exposure of c-Rel-driven breast cancer cells further activated NF-KB, which was required for an
invasive phenotype; (3) the c-Rel subunit can play a causal role in mammary tumorigenesis and cooperated
with protein kinase CK2 to induce the AhR and Slug, a master regulator of EMT; (4) a novel de novo RelB
synthesis pathway was identified, which promoted EMT via induction of Bcl-2; (5) RelB was induced by
DMBA or c-Rel and expressed in human breast cancer specimens. Of note, green tea and its polyphenol
epigallocatechin-3 gallate (EGCG) reduced invasive phenotype of DMBA-induced mammary tumors and
breast cancer cells. EGCG slowed proliferation of Her-2/neu breast cancer cell lines resistant to
trastuzumab, suggesting translational applications of green tea polyphenols. Thus, environmental
carcinogens are known to induce genetic as well as epigenetic events in mammary tissue. In this revised
renewal application, we propose to test the hypothesis that these perturbations induce or enhance the
activity of multiple NF-KB complexes thereby promoting a more invasive phenotype of breast cancer: thus
inhibition of these pathways will revert the process of EMT. Three aims are proposed: (1) elucidate the roles
of c-Rel and RelB NF-KB in promoting carcinogenesis; (2) determine the function of IKKe/i in carcinogenesis,
and the mechanism of IKKs/i promoter activation; (3) perform pre-clinical in vivo testing of the ability of green
tea polyphenols to reduce Her-2/neu-mediated transformation. These studies will provide important
information on the mechanisms of activation of aberrant expression of NF-KB factors by environmental
carcinogens, and characterize their roles in promoting invasive breast cancer. Green tea polyphenols are
potential inhibitors of breast cancer that can readily be translated to the clinic for combinatorial therapies.
National Institute of Environmental Health Sciences
CFDA Code
DUNS Number
039318308
UEI
C1F5LNUF7W86
Project Start Date
Project End Date
Budget Start Date
01-July-2010
Budget End Date
30-June-2011
Project Funding Information for 2009
Total Funding
$167,648
Direct Costs
$103,167
Indirect Costs
Year
Funding IC
FY Total Cost by IC
2009
National Institute of Environmental Health Sciences
$167,648
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 7P01ES011624-08 0003
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 7P01ES011624-08 0003
Patents
No Patents information available for 7P01ES011624-08 0003
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 7P01ES011624-08 0003
Clinical Studies
No Clinical Studies information available for 7P01ES011624-08 0003
News and More
Related News Releases
No news release information available for 7P01ES011624-08 0003
History
No Historical information available for 7P01ES011624-08 0003
Similar Projects
No Similar Projects information available for 7P01ES011624-08 0003